OncoTherapy Science Overview
- Founded
-
2001
- Status
-
Public
- Employees
-
73
- Stock Symbol
-
4564
- Share Price
-
$0.39
- (As of Friday Closing)
OncoTherapy Science General Information
Description
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
TKS
Primary Office
- 3-2-1 Sakado
- Kawasaki-shi
- Kanagawa, Takatsu-ku 213-0012
- Japan
+81 000-000-0000
OncoTherapy Science Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.39 | $0.39 | $0.37 - $0.60 | $75.1M | 193M | 964K | -$0.05 |
OncoTherapy Science Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 66,237 | 89,605 | 163,698 | 60,109 |
| Revenue | 11,552 | 10,269 | 3,135 | 2,908 |
| EBITDA | (22,736) | (14,259) | (20,215) | |
| Net Income | (10,239) | (22,890) | (14,727) | (20,588) |
| Total Assets | 11,013 | 22,001 | 30,532 | 47,080 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
OncoTherapy Science Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OncoTherapy Science Patents
OncoTherapy Science Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3108403-A1 | Cdca1-derived peptide and vaccine containing same | Pending | 02-Aug-2018 | 00000000 | |
| EP-3831943-A4 | Cdca1-derived peptide and vaccine containing same | Pending | 02-Aug-2018 | 00000000 | 0 |
| US-20210371462-A1 | Cdca1-derived peptide and vaccine containing same | Pending | 02-Aug-2018 | 00000000000 | |
| EP-3831943-A1 | Cdca1-derived peptide and vaccine containing same | Pending | 02-Aug-2018 | 00000000 | |
| JP-WO2020027239-A1 | Cdca1-derived peptide and vaccine containing it | Pending | 02-Aug-2018 | C07K7/06 |
OncoTherapy Science Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Park Wise | Chief Executive Officer & President | ||
| Hajime Kato | Executive Chairman |
OncoTherapy Science Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chung Shuren | OncoTherapy Science | Board Member | 000 0000 |
| Hajime Kato | OncoTherapy Science | Executive Chairman | 000 0000 |
| Tomoaki Fujioka | OncoTherapy Science | Board Member | 000 0000 |
| Toyomasa Katagiri | OncoTherapy Science | Board Member | 000 0000 |
| Yuichi Komine | OncoTherapy Science | Board Member | 000 0000 |
OncoTherapy Science Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OncoTherapy Science ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
